VOCLOSPORIN-BASED, TRIPLE-IMMUNOSUPPRESSIVE REGIMEN VERSUS HIGH-DOSE GLUCOCORTICOID AND MYCOPHENOLATE MOFETIL-BASED THERAPY FOR LUPUS NEPHRITIS: A PROPENSITY ANALYSIS OF THE ALMS, AURA-LV AND AURORA 1 STUDIES (EULAR 2024) - Mar 29, 2024 - Abstract #OP0059; Pres time: Jun 12, 2024; 05:10 PM - 05:20 PM; Location: C8; "However, dual-immunosuppressive regimens containing high-dose glucocorticoids (GCs) and higher doses (>2 g/day) of mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC) are still frequently used for the management of active LN in the belief that they may be more efficacious and safer. Participants treated with voclosporin in combination with low-dose GCs and MMF 2g/day demonstrated an improved safety profile and earlier reductions in proteinuria compared to participants treated with high-dose GCs and MMF up to 3 g/day or IVC. These findings support the recommendation that a voclosporin-based, triple-immunosuppressive regimen should be considered as an initial therapy in patients with active LN."
Anemia • Cardiovascular • Glomerulonephritis • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
A. Askanase1; K. C. Kalunian2; M. Dall'era3; N. Solomons4; L. Hodge5; M. Truman5; E. Yap5
|